This study offers an insight into the pharmaceutical industry of Ethiopia, where preference for generic, prescription drugs is growing. There is information on recent reforms introduced by the government (like tax benefits for in-country production, national strategy, and plan of action for pharmaceutical manufacturing development, growth and transformation plan, and so on), key participants in the market, population and disease statistics, and so on.
The study also describes the opportunities and constraints in the market and revenue forecasts for the total market from 2011-2020. Primary research interviews with industry stakeholders and secondary research through in-house database and news reports were undertaken.
Key Questions this Study will Answer:
- Is the pharmaceutical market in Ethiopia growing; how long will it continue to grow, and at what rate?
- How is the government contributing towards the growth of the pharmaceutical industry in Ethiopia?
- Growth of which segment (prescription drugs and non-prescription drugs) and which subsegment (generic drugs and branded drugs) is being favored by the market?
- What are the fastest growing product and therapeutic segments in the pharmaceutical industry of Ethiopia?
- What are the key drivers and restraints affecting the growth of the pharmaceutical industry in Ethiopia? What are the key challenges that may be faced in the near future and the long term?
- Are the pharmaceutical drugs offered today meeting the needs of patients in Ethiopia or is there a need for additional development?
- How is the pharmaceutical market segmented in Ethiopia? Of the types of medicines and various therapeutic areas, which ones will grow in the near future and in the long term?
Key Topics Covered
1. Executive Summary
2. Market Overview
3. Competitive Playbook
4. Drivers, Restraints, and Trends-Total Pharmaceutical Market
5. Forecast and Trends-Total Pharmaceutical Market
6. Competitive Environment
7. Key Companies to Watch
8. The Last Word
– Addis Pharmaceutical Factory PLC
– Aurobindo Pharma Limited
– Cadila Pharmaceutical Limited
– GlaxoSmithKline PLC
– Julphar (Gulf Pharmaceutical Industries)
– Novartis International AG
For more information visit http://www.researchandmarkets.com/research/tq8z8z/analysis_of_the
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Source: Business Wire
- EPHARM Is Up for the Construction of $100M Pharmaceutical
- Africa’s First Insulin Factory Construction to Launch in April
- 54 Capital Plans Ethiopian Pharma Factory after $30 Million Deal
- Kilitch Drugs (India) Ltd. forms JV in Ethiopia with Local Partner